Ask Onix
Novo Nordisk files lawsuit to block rival's weight-loss products
Novo Nordisk, the Danish manufacturer of Ozempic and Wegovy, has taken legal action against Hims & Hers, accusing the company of selling unapproved and potentially unsafe imitations of its weight-loss medications in the U.S.
Legal dispute escalates after product launch
The conflict began last Friday when Hims & Hers introduced a new weight-loss pill, prompting an immediate warning from Novo Nordisk. Over the weekend, Hims & Hers announced it would halt sales of the pill. Despite this, Novo Nordisk proceeded with a lawsuit on Monday, calling the move a "blatant attack" on competition.
Hims & Hers' stock fell 16% by market close on Monday, while Novo Nordisk's shares saw a slight increase early Tuesday.
Patent protection and public health concerns
Novo Nordisk stated that its lawsuit aims to "protect public health and defend the scientific innovations that deliver better health outcomes to Americans." The company argued that Hims & Hers' products, which are compounded rather than FDA-approved, could contain harmful impurities or incorrect dosages, posing serious health risks.
In response, Hims & Hers defended its practices, stating it has "a long history of providing safe access to personalized healthcare" and accused Novo Nordisk of "weaponizing the U.S. judicial system to limit consumer choice."
FDA steps in amid rising copycat drug concerns
The U.S. Food and Drug Administration (FDA) announced Friday that it would tighten restrictions on compounded weight-loss drugs, citing concerns over unverified safety and efficacy. Novo Nordisk referenced these FDA warnings in its lawsuit, emphasizing the potential dangers of unregulated alternatives.
Pharmaceutical analyst Kerry Fulford of Berenberg described Novo Nordisk's legal action as its "first move to clamp down on compounding," a legal process allowing U.S. drugmakers to produce unapproved medications for patients with specific needs.
Novo Nordisk faces broader challenges
The Danish firm has faced a turbulent period, including thousands of job cuts announced in September and a recent profit warning due to expiring patents. Additionally, the FDA criticized a Wegovy television advertisement last Thursday, calling it misleading for suggesting benefits beyond physical weight loss, such as emotional relief.
Novo Nordisk responded that it "takes all regulatory feedback seriously" and is addressing the FDA's concerns.
Industry impact and next steps
The lawsuit highlights growing tensions in the weight-loss drug market, where demand for medications like Ozempic, Wegovy, Zepbound, and Mounjaro has surged. The rise of low-cost copycat drugs has raised safety concerns, prompting regulatory scrutiny and legal battles over patent protection and public health.
